New drug cocktail aims to shrink Hard-to-Treat tumors
NCT ID NCT07331155
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called LBL-024 combined with standard chemotherapy and immunotherapy for people with advanced solid tumors. About 110 adults with good overall health will receive the treatment to see if tumors shrink or stop growing. The goal is to find a safer and more effective option for those who have limited choices.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LBL-024 (an experimental drug) combined with chemotherapy drugs (cisplatin, paclitaxel, 5-fluorouracil, capecitabine) and tislelizumab (an immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that are hard to treat.
What could go wrong
This is an early Phase 2 trial with only 110 participants, so results may not apply to everyone. The combination therapy may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AnYang Tumor Hospital
NOT_YET_RECRUITINGAnyang, Henan, 455000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Suining Central Hospital
RECRUITINGSuining, Sichuan, 629099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Henan University of Science & Technology
RECRUITINGLuoyang, Henan, 471003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 451191, China
Contact Phone: •••-•••-•••• Email: •••••@•••••